Nucelion Therapeutics, VeGen Bio partner on India CAR-T manufacturing
In short
Nucelion Therapeutics and VeGen Bio have agreed to work together to make CAR-T cell therapy in India. The plan includes technology transfer, clinical and commercial manufacturing, and better production processes.
This could help lower costs and make treatment reach more patients. The report does not say the deal value, when it starts, or where the manufacturing will happen.
What the reporting says
Nucelion Therapeutics and VeGen Bio agreed to partner on manufacturing CAR-T cell therapy in India, according to a BusinessLine summary. The collaboration will combine technology transfer, clinical and commercial manufacturing, and process optimisation to improve production economics and widen patient access. The immediate consequence is a planned manufacturing tie-up, while the reporting does not state contract value, timeline or facility details.
Why it matters
Nucelion Therapeutics and VeGen Bio announced a collaboration to manufacture CAR-T cell therapy in India. BusinessLine’s summary says the partnership covers technology transfer, clinical and commercial manufacturing, and process optimisation, with the aim of improving production economics and patient access. The development is positive for both companies and for the broader cell-therapy ecosystem, but the available reporting does not specify commercial terms, timelines or capacity.